CC
PRTK

Caxton Corporation’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Caxton Corporation’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,456
Closed -$300K – 17
2017
Q2 		$300K Buy
+12,456
New +$275K 0.47% 10
2017
Q1 		– Sell
-21,923
Closed -$338K – 12
2016
Q4 		$338K Buy
21,923
+3,014
+16% +$39.1K 1.15% 7
2016
Q3 		$246K Hold
18,909
– – 1.1% 6
2016
Q2 		$263K Buy
+18,909
New +$278K 0.3% 8

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Caxton Corporation's PRTK Position: Q3 2017 in Review

Caxton Corporation sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 12,456 shares — an estimated $300K sold.

Caxton Corporation first reported a position in PRTK in Q2 2016 and held it in 4 quarters. The position peaked at $338K in Q4 2016. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • Caxton Corporation reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Caxton Corporation sold 12,456 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $300K.
  • Caxton Corporation first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 4 quarters.
  • Caxton Corporation's Paratek Pharmaceuticals, Inc. position peaked at $338K in Q4 2016.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Caxton Corporation's 13F filing for Q3 2017, filed 14 Nov 2017.